SPONSORS AND SUPPORTERS:
|Indivior is the world leader in addiction treatment with over 20 years’ experience and a unique patient‐focused approach. Our endeavour is to understand the journey of individuals suffering with addiction.
We partner with healthcare professionals, the public health community, policymakers, and payers to ensure people suffering from addiction are treated just like any other patients suffering from a chronic, relapsing medical condition.
At Indivior our endeavour is to focus on individual patients around the world. The patient continues to drive our decisions.
Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision of ensuring unrestricted access to high‐quality treatments for the chronic relapsing conditions and co-morbidities of addiction.
|Gilead’s mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including Haematology/Oncology (ZYDELIG® [idelalisib]), HIV (DESCOVY® [emtricitabine/tenofovir alafenamide], GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide], STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat], EVIPLERA® [tenofovir disoproxil fumarate & emtricitabine & rilpivirine], ATRIPLA® [tenofovir disoproxil fumarate & emtricitabine & efavirenz], TRUVADA® [emtricitabine & tenofovir disoproxil fumarate], EMTRIVA® [emtricitabine], VIREAD® [tenofovir disoproxil fumarate]), chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate], HEPSERA® [adefovir dipivoxil]), chronic hepatitis C (EPCLUSA® [sofosbovir/velpatasvir], HARVONI® [ledipasvir & sofosbovir], SOVALDI® [sofosbuvir]), and systemic fungal infections (AmBisome® [liposomal amphotericin B])|
|Camurus is a Swedish research-based pharmaceutical company committed to developing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary lipid-based FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of opioid dependence, pain, cancer and endocrine diseases, developed in-house and in collaboration with international pharmaceutical companies.|
|AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Our heritage in Australia reaches back more than 75 years and we employ more than 225 people here with a focus on Immunology, Liver Disease, Neuroscience and Oncology, and our therapies currently benefit more than 32,000 Australians.|
|Travel Scholarship Supporter|